225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts
Although a lot of progress has been made in the treatment of clear cell renal cell carcinoma (ccRCC), the prognosis of patients with metastasized tumors remains poor. Therefore, novel treatment options need to be developed. A rapidly advancing field of interest is targeted radionuclide therapy using α-emitting radionuclides, such as actinium-225 (225Ac). Carbonic anhydrase IX (CAIX) is over expressed in ccRCC and can be targeted effectively using the monoclonal antibody girentuximab. The aim of this preclinical study was to radiolabel girentuximab with actinium-225 and assess its in vivo tumor targeting properties, therapeutic efficacy and toxicity in mice.
MERKX Robin;
HESKAMP Sandra;
MULDERS Peter;
RIJPKEMA Mark;
OOSTERWIJK Egbert;
WHEATCROFT Michael;
KIP Annemarie;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
2019-07-24
ELSEVIER BV
JRC116486
1939-8654 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC116486,
10.1016/j.jmir.2019.03.079 (online),
Additional supporting files
| File name | Description | File type | |
|---|
